Guidance: Cancer Clinical Trial Eligibility Criteria: Performance Status
FDA issued guidance on performance status criteria for cancer clinical trial eligibility, aiming to broaden access. No immediate regulatory action required for manufacturing or drug approval processes.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: None. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA published guidance on performance status eligibility criteria for cancer clinical trials, but this does not alter cGMP, drug approval, or DEA compliance requirements.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
No action required; monitor for future updates if your business conducts cancer clinical trials.
Deadline
None
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Section 301 Action: Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure of Each Economy to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor
- Guidance: Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
- DOJ Moves FDA Approved and Medical Marijuana to Schedule III - ArentFox Schiff
- FDA Proposes to Eliminate "Adequate Provision" for Broadcast Prescription Drug Advertising - Foley Hoag
- US-CONGRESS S5004: Cancer Drug Parity Act of 2026